Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Aug;18(2):207–214. doi: 10.1111/j.1365-2125.1984.tb02454.x

Naproxen pharmacokinetics in the elderly.

R A Upton, R L Williams, J Kelly, R M Jones
PMCID: PMC1463512  PMID: 6487459

Abstract

While naproxen pharmacokinetics appear to be altered in the presence of both diminished renal and hepatic function, the degree to which naproxen disposition might be influenced in the elderly by concurrent alteration in these functions is not obvious. Total plasma clearance/bioavailability (CL/F) of naproxen after a single 375 mg oral dose was found to be less in a group of 10 healthy men between 66 and 81 years of age than in 10 healthy men between 22 and 39 years (0.318 +/- 0.078, 0.416 +/- 0.061 l/h). At steady state (375 mg, 12 hourly), however, CL/F was statistically indistinguishable between the two groups. The fraction of naproxen unbound to plasma protein was doubled in elderly subjects, both at peak and trough drug concentrations. The lowered protein binding tended to obscure a 50% decrement in the intrinsic clearance of naproxen in the elderly as estimated by unbound clearance/bioavailability (213 +/- 64, 396 +/- 155 l/h). As a result, mean steady-state plasma concentrations of naproxen were indistinguishable between the elderly and young (64.2 +/- 8.5, 58.2 +/- 8.1 mg/l) but the elderly generated twice the mean steady-state unbound plasma drug concentration (0.157 +/- 0.039, 0.0859 +/- 0.0212 mg/l). Since it is the unbound drug concentration which appears in general to relate more closely to pharmacological and toxic effect, it may be advisable to reduce naproxen doses by half in the elderly, pending plasma drug concentration-response studies in this age group. If a similar perturbation with age occurs in benoxaprofen protein binding as was observed with naproxen, benoxaprofen intrinsic clearance in the elderly might be only one quarter of that in younger individuals; a factor which may contribute to the toxicity of this drug in the elderly.

Full text

PDF
207

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anttila M., Haataja M., Kasanen A. Pharmacokinetics of naproxen in subjects with normal and impaired renal function. Eur J Clin Pharmacol. 1980 Oct;18(3):263–268. doi: 10.1007/BF00563009. [DOI] [PubMed] [Google Scholar]
  2. Aronoff G. R., Ozawa T., DeSante K. A., Nash J. F., Ridolfo A. S. Benoxaprofen kinetics in renal impairment. Clin Pharmacol Ther. 1982 Aug;32(2):190–194. doi: 10.1038/clpt.1982.146. [DOI] [PubMed] [Google Scholar]
  3. Boost G. Klinisch-pharmakologische und pharmakokinetische Studien mit Naproxen. Arzneimittelforschung. 1975 Feb;25(2A):281–287. [PubMed] [Google Scholar]
  4. Chiou W. L. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level--time curve. J Pharmacokinet Biopharm. 1978 Dec;6(6):539–546. doi: 10.1007/BF01062108. [DOI] [PubMed] [Google Scholar]
  5. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  6. Goudie B. M., Birnie G. F., Watkinson G., MacSween R. N., Kissen L. H., Cunningham N. E. Jaundice associated with the use of benoxaprofen. Lancet. 1982 Apr 24;1(8278):959–959. doi: 10.1016/s0140-6736(82)91953-5. [DOI] [PubMed] [Google Scholar]
  7. Hamdy R. C., Murnane B., Perera N., Woodcock K., Koch I. M. The pharmacokinetics of benoxaprofen in elderly subjects. Eur J Rheumatol Inflamm. 1982;5(2):69–75. [PubMed] [Google Scholar]
  8. Held H. Serumprotein bindung und Eliminationshalbwertszeiten von Naproxen bei Patienten mit hepatozellulärem bzw. obstruktivem Ikterus. Arzneimittelforschung. 1980;30(5):843–846. [PubMed] [Google Scholar]
  9. Nash J. F., Carmichael R. H., Ridolfo A. S., Spradlin C. T. Pharmacokinetic studies of benoxaprofen after therapeutic doses with a review of related pharmacokinetic and metabolic studies. J Rheumatol Suppl. 1980;6:12–19. [PubMed] [Google Scholar]
  12. Runkel R., Chaplin M., Boost G., Segre E., Forchielli E. Absorption, distribution, metabolism, and excretion of naproxen in various laboratory animals and human subjects. J Pharm Sci. 1972 May;61(5):703–708. doi: 10.1002/jps.2600610507. [DOI] [PubMed] [Google Scholar]
  13. Runkel R., Mroszczak E., Chaplin M., Sevelius H., Segre E. Naproxen-probenecid interaction. Clin Pharmacol Ther. 1978 Dec;24(6):706–713. doi: 10.1002/cpt1978246706. [DOI] [PubMed] [Google Scholar]
  14. Taggart H. M., Alderdice J. M. Fatal cholestatic jaundice in elderly patients taking benoxaprofen. Br Med J (Clin Res Ed) 1982 May 8;284(6326):1372–1372. doi: 10.1136/bmj.284.6326.1372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Tozer T. N., Gambertoglio J. G., Furst D. E., Avery D. S., Holford N. H. Volume shifts and protein binding estimates using equilibrium dialysis: application to prednisolone binding in humans. J Pharm Sci. 1983 Dec;72(12):1442–1446. doi: 10.1002/jps.2600721218. [DOI] [PubMed] [Google Scholar]
  16. Triggs E. J., Nation R. L. Pharmacokinetics in the aged: a review. J Pharmacokinet Biopharm. 1975 Dec;3(6):387–418. doi: 10.1007/BF01059473. [DOI] [PubMed] [Google Scholar]
  17. Upton R. A., Buskin J. N., Guentert T. W., Williams R. L., Riegelman S. Convenient and sensitive high-performance liquid chromatography assay for ketoprofen, naproxen and other allied drugs in plasma or urine. J Chromatogr. 1980 Mar 21;190(1):119–128. doi: 10.1016/s0021-9673(00)85518-1. [DOI] [PubMed] [Google Scholar]
  18. Upton R. A., Buskin J. N., Williams R. L., Holford N. H., Riegelman S. Negligible excretion of unchanged ketoprofen, naproxen, and probenecid in urine. J Pharm Sci. 1980 Nov;69(11):1254–1257. doi: 10.1002/jps.2600691105. [DOI] [PubMed] [Google Scholar]
  19. Upton R. A., Williams R. L., Buskin J. N., Jones R. M. Effects of probenecid on ketoprofen kinetics. Clin Pharmacol Ther. 1982 Jun;31(6):705–712. doi: 10.1038/clpt.1982.99. [DOI] [PubMed] [Google Scholar]
  20. Vestal R. E. Drug use in the elderly: a review of problems and special considerations. Drugs. 1978 Oct;16(4):358–382. doi: 10.2165/00003495-197816040-00004. [DOI] [PubMed] [Google Scholar]
  21. Yeh K. C., Kwan K. C. A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation. J Pharmacokinet Biopharm. 1978 Feb;6(1):79–98. doi: 10.1007/BF01066064. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES